Equillium, Inc. EQ

EQ Company Overview

Equillium, Inc. is a U.S.-based biotechnology company focused on developing therapeutics for severe autoimmune and inflammatory disorders with high unmet medical need. The company operates within the biopharmaceutical and immunology sectors and primarily develops immune-modulating therapies intended to address conditions driven by dysregulated T-cell and cytokine activity. Its core value proposition centers on targeting immune pathways associated with graft-versus-host disease, alopecia areata, lupus nephritis, inflammatory bowel disease, and other immune-mediated diseases.

The company’s principal product candidate has been itolizumab, a monoclonal antibody targeting CD6, although Equillium has also expanded its pipeline through additional immunology-focused assets and strategic collaborations. Revenue generation has historically been limited because the company remains in the clinical-stage biotechnology phase and has not commercialized a product as of publicly available filings. Equillium was founded in 2017 and became publicly traded on Nasdaq under the ticker EQ. The company evolved from a single-asset immunology platform into a broader immune-modulation pipeline through licensing arrangements, development partnerships, and internal clinical development initiatives.